![Thomas Biancardi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Biancardi
Keine laufenden Positionen mehr
Karriereverlauf von Thomas Biancardi
Ehemalige bekannte Positionen von Thomas Biancardi
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - | - |
IVERIC BIO, INC. | Geschäftsführer | 01.09.2007 | 31.01.2012 |
Investor Relations Kontakt | 29.08.2013 | 14.01.2015 | |
Public Communications Contact | 01.09.2007 | - | |
Corporate Officer/Principal | 19.08.2013 | - | |
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Geschäftsführer | - | - |
Finanzdirektor/CFO | - | - |
Ausbildung von Thomas Biancardi
New York University | Masters Business Admin |
Rutgers State University of New Jersey | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Chief Operating Officer | 2 |
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
IVERIC bio, Inc.
![]() IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
- Börse
- Insiders
- Thomas Biancardi
- Erfahrung